Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California. more
Time Frame | BCAB | Sector | S&P500 |
---|---|---|---|
1-Week Return | -11.59% | -2.27% | -0.57% |
1-Month Return | -27.14% | -3.96% | 1.21% |
3-Month Return | -19.89% | -9.7% | 7.57% |
6-Month Return | -7.64% | -3.37% | 11.45% |
1-Year Return | -31.6% | 3.71% | 28.48% |
3-Year Return | -93.35% | 3.8% | 29.52% |
5-Year Return | -95.33% | 39.78% | 90.66% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 5.20M | 429.00K | 250.00K | - | - | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":8.25,"profit":true},{"date":"2021-12-31","value":4.81,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 25.92K | 19.93K | 1.33M | 1.20M | 103.73M | [{"date":"2019-12-31","value":0.02,"profit":true},{"date":"2020-12-31","value":0.02,"profit":true},{"date":"2021-12-31","value":1.28,"profit":true},{"date":"2022-12-31","value":1.16,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 5.17M | 409.07K | (1.08M) | (1.20M) | (103.73M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":7.91,"profit":true},{"date":"2021-12-31","value":-20.87,"profit":false},{"date":"2022-12-31","value":-23.17,"profit":false},{"date":"2023-12-31","value":-2004.82,"profit":false}] |
Gross Margin | 99.50% | 95.35% | (432.00%) | - | - | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":95.83,"profit":true},{"date":"2021-12-31","value":-434.16,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 33.47M | 30.53M | 96.69M | 108.14M | 129.69M | [{"date":"2019-12-31","value":25.81,"profit":true},{"date":"2020-12-31","value":23.54,"profit":true},{"date":"2021-12-31","value":74.56,"profit":true},{"date":"2022-12-31","value":83.39,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (28.27M) | (30.10M) | (96.44M) | (108.14M) | (129.69M) | [{"date":"2019-12-31","value":-2826800000,"profit":false},{"date":"2020-12-31","value":-3009900000,"profit":false},{"date":"2021-12-31","value":-9644000000,"profit":false},{"date":"2022-12-31","value":-10814000000,"profit":false},{"date":"2023-12-31","value":-12968700000,"profit":false}] |
Total Non-Operating Income/Expense | (3.09M) | (7.04M) | 1.39M | 3.31M | 11.95M | [{"date":"2019-12-31","value":-25.86,"profit":false},{"date":"2020-12-31","value":-58.96,"profit":false},{"date":"2021-12-31","value":11.59,"profit":true},{"date":"2022-12-31","value":27.67,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (29.86M) | (35.85M) | (95.40M) | (106.48M) | (123.46M) | [{"date":"2019-12-31","value":-2985500000,"profit":false},{"date":"2020-12-31","value":-3585300000,"profit":false},{"date":"2021-12-31","value":-9540200000,"profit":false},{"date":"2022-12-31","value":-10648200000,"profit":false},{"date":"2023-12-31","value":-12346200000,"profit":false}] |
Income Taxes | 1.55M | 1.39M | 4.00K | (1.20M) | - | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":89.72,"profit":true},{"date":"2021-12-31","value":0.26,"profit":true},{"date":"2022-12-31","value":-77.5,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | (31.40M) | (37.24M) | (95.41M) | (105.28M) | - | [{"date":"2019-12-31","value":-3140200000,"profit":false},{"date":"2020-12-31","value":-3724100000,"profit":false},{"date":"2021-12-31","value":-9540600000,"profit":false},{"date":"2022-12-31","value":-10528300000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (29.86M) | (35.85M) | (95.40M) | (106.48M) | (124.08M) | [{"date":"2019-12-31","value":-2985500000,"profit":false},{"date":"2020-12-31","value":-3585300000,"profit":false},{"date":"2021-12-31","value":-9540200000,"profit":false},{"date":"2022-12-31","value":-10648200000,"profit":false},{"date":"2023-12-31","value":-12408000000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (31.40M) | (37.24M) | (95.41M) | (105.28M) | (123.46M) | [{"date":"2019-12-31","value":-3140200000,"profit":false},{"date":"2020-12-31","value":-3724100000,"profit":false},{"date":"2021-12-31","value":-9540600000,"profit":false},{"date":"2022-12-31","value":-10528300000,"profit":false},{"date":"2023-12-31","value":-12346200000,"profit":false}] |
EPS (Diluted) | - | (2.33) | (2.76) | (2.74) | (2.59) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-233,"profit":false},{"date":"2021-12-31","value":-276,"profit":false},{"date":"2022-12-31","value":-274,"profit":false},{"date":"2023-12-31","value":-259.06,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
BCAB | |
---|---|
Cash Ratio | 2.90 |
Current Ratio | 3.11 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
BCAB | |
---|---|
ROA (LTM) | -50.47% |
ROE (LTM) | -139.06% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
BCAB | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.63 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.37 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
BCAB | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 6.37 |
P/B | 3.05 |
Price/FCF | NM |
EV/R | 1.24 |
EV/Ebitda | 0.31 |
Bioatla Inc (BCAB) share price today is $1.45
Yes, Indians can buy shares of Bioatla Inc (BCAB) on Vested. To buy Bioatla Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in BCAB stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Bioatla Inc (BCAB) via the Vested app. You can start investing in Bioatla Inc (BCAB) with a minimum investment of $1.
You can invest in shares of Bioatla Inc (BCAB) via Vested in three simple steps:
The 52-week high price of Bioatla Inc (BCAB) is $4.02. The 52-week low price of Bioatla Inc (BCAB) is $1.14.
The price-to-earnings (P/E) ratio of Bioatla Inc (BCAB) is
The price-to-book (P/B) ratio of Bioatla Inc (BCAB) is 3.05
The dividend yield of Bioatla Inc (BCAB) is 0.00%
The market capitalization of Bioatla Inc (BCAB) is $73.97M
The stock symbol (or ticker) of Bioatla Inc is BCAB